About
enGene Therapeutics
ENGN.US
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2.
Profile
- Company Name
- enGene Therapeutics Inc.
- Market
- NasdaqCM
- Founded
- --
- Industry
- --
- Fiscal Year End
- October 31
- Website
- www.engene.com